An HDAC inhibitor enhances cancer therapeutic efficiency of RNA polymerase III promoter-driven IDO shRNA.

about

Transcription. Comment on "Mechanism of eukaryotic RNA polymerase III transcription termination".Neutrophils are Essential in Short Hairpin RNA of Indoleamine 2,3- Dioxygenase Mediated-antitumor Efficiency

P2860

Q34149130-AA651986-7792-4280-ACCE-690BF37FEC75 Q37507487-8CFC78D5-562A-4076-9145-E3E443C4F652

P2860

An HDAC inhibitor enhances cancer therapeutic efficiency of RNA polymerase III promoter-driven IDO shRNA.

Item

http://www.wikidata.org/entity/Q39150897

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

An HDAC inhibitor enhances can ...... III promoter-driven IDO shRNA.

@en

An HDAC inhibitor enhances can ...... III promoter-driven IDO shRNA.

@nl

type

Item

label

An HDAC inhibitor enhances can ...... III promoter-driven IDO shRNA.

@en

An HDAC inhibitor enhances can ...... III promoter-driven IDO shRNA.

@nl

prefLabel

An HDAC inhibitor enhances can ...... III promoter-driven IDO shRNA.

@en

An HDAC inhibitor enhances can ...... III promoter-driven IDO shRNA.

@nl

P1476

An HDAC inhibitor enhances can ...... III promoter-driven IDO shRNA

@en

P2093

C-C Lin

http://www.w3.org/2001/XMLSchema#string

C-S Chen

http://www.w3.org/2001/XMLSchema#string

C-Y Chen

http://www.w3.org/2001/XMLSchema#string

C-Y Wang

http://www.w3.org/2001/XMLSchema#string

H-L Chao

http://www.w3.org/2001/XMLSchema#string

M-D Lai

http://www.w3.org/2001/XMLSchema#string

T-Y Weng

http://www.w3.org/2001/XMLSchema#string

Y-L Chen

http://www.w3.org/2001/XMLSchema#string

P2860

The many roles of histone deacetylases in development and physiology: implications for disease and therapy

DNA vaccines: improving expression of antigens

A system for stable expression of short interfering RNAs in mammalian cells

The epigenomics of cancer

Histone deacetylase inhibitors: new hope for rheumatoid arthritis?

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.

The clinical development of histone deacetylase inhibitors as targeted anticancer drugs.

Histone acetylation: influence on transcription, nucleosome mobility and positioning, and linker histone-dependent transcriptional repression.

The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines.

Histone deacetylases and cancer: causes and therapies.

P2888

cgt.2013.27

P304

351-357

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CGT.2013.27

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Meng-Chi Yen

P577

2013-05-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236915777

http://www.w3.org/2001/XMLSchema#string

P698

23681283

http://www.w3.org/2001/XMLSchema#string

An HDAC inhibitor enhances cancer therapeutic efficiency of RNA polymerase III promoter-driven IDO shRNA.

about

P2860

P2860

An HDAC inhibitor enhances cancer therapeutic efficiency of RNA polymerase III promoter-driven IDO shRNA.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P5875

P698